Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 183

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Metoprolol for the Prevention of Acute Exacerbations of COPD

Open access
Dransfield, Mark T., Voelker, Helen, Bhatt, Surya P., Brenner, Keith, Casaburi, Richard, Come, Carolyn E., Cooper, J. Allen D., Criner, Gerard J., Curtis, Jeffrey L., Han, MeiLan K., Hatipoğlu, Umur, Helgeson, Erika S., Jain, Vipul V., Kalhan, Ravi, Kaminsky, David, Kaner, Robert, Kunisaki, Ken M., Lambert, Allison A., Lammi, Matthew R., Lindberg, Sarah, Make, Barry J., Martinez, Fernando J., McEvoy, Charlene, Panos, Ralph J., Reed, Robert M., Scanlon, Paul D., Sciurba, Frank C., Smith, Anthony, Sriram, Peruvemba S., Stringer, William W., Weingarten, Jeremy A., Wells, J. Michael, Westfall, Elizabeth, Lazarus, Stephen C., Connett, John E.·2019·New England Journal of Medicine

Abstract

BACKGROUND: Observational studies suggest that beta-blockers may reduce the risk of exacerbations and death in patients with moderate or severe chronic obstructive pulmonary disease (COPD), but these findings have not been confirmed in randomized trials. METHODS: In this prospective, randomized trial, we assigned patients between the ages of 40 and 85 years who had COPD to receive either a beta-blocker (extended-release metoprolol) or placebo. All the patients had a clinical history of COPD, along with moderate airflow limitation and an increased risk of exacerbations, as evidenced by a history of exacerbations during the previous year or the prescribed use of supplemental oxygen. We excluded patients who were already taking a beta-blocker or who had an established indication for the use of such drugs. The primary end point was the time until the first exacerbation of COPD during the treatment period, which ranged from 336 to 350 days, depending on the adjusted dose of metoprolol. RESULTS: ) was 41.1±16.3% of the predicted value. The trial was stopped early because of futility with respect to the primary end point and safety concerns. There was no significant between-group difference in the median time until the first exacerbation, which was 202 days in the metoprolol group and 222 days in the placebo group (hazard ratio for metoprolol vs. placebo, 1.05; 95% confidence interval [CI], 0.84 to 1.32; P = 0.66). Metoprolol was associated with a higher risk of exacerbation leading to hospitalization (hazard ratio, 1.91; 95% CI, 1.29 to 2.83). The frequency of side effects that were possibly related to metoprolol was similar in the two groups, as was the overall rate of nonrespiratory serious adverse events. During the treatment period, there were 11 deaths in the metoprolol group and 5 in the placebo group. CONCLUSIONS: Among patients with moderate or severe COPD who did not have an established indication for beta-blocker use, the time until the first COPD exacerbation was similar in the metoprolol group and the placebo group. Hospitalization for exacerbation was more common among the patients treated with metoprolol. (Funded by the Department of Defense; BLOCK COPD ClinicalTrials.gov number, NCT02587351.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1908142

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 183

Metadata

Authors
Dransfield, M. T., Voelker, H., Bhatt, S. P., Brenner, K., Casaburi, R., Come, C. E., Cooper, J. A. D., Criner, G. J., Curtis, J. L., Han, M. K., Hatipoğlu, U., Helgeson, E. S., Jain, V. V., Kalhan, R., Kaminsky, D., Kaner, R., Kunisaki, K. M., Lambert, A. A., Lammi, M. R., Lindberg, S., Make, B. J., Martinez, F. J., McEvoy, C., Panos, R. J., Reed, R. M., Scanlon, P. D., Sciurba, F. C., Smith, A., Sriram, P. S., Stringer, W. W., Weingarten, J. A., Wells, J. M., Westfall, E., Lazarus, S. C., & Connett, J. E.
Venue
New England Journal of Medicine
Published
2019-12-12
Volume
381
Issue
24
Pages
2304-2314
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2980413596
Cited by
183
References
6
FWCI
13.67
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metoprolol for the Prevention of Acute Exacerbations of COPD. https://app.cochat.ai/papers/10.1056/nejmoa1908142
The paper
Dransfield, M. T., Voelker, H., Bhatt, S. P., Brenner, K., Casaburi, R., Come, C. E., Cooper, J. A. D., Criner, G. J., Curtis, J. L., Han, M. K., Hatipoğlu, U., Helgeson, E. S., Jain, V. V., Kalhan, R., Kaminsky, D., Kaner, R., Kunisaki, K. M., Lambert, A. A., Lammi, M. R., . . . Connett, J. E. (2019). Metoprolol for the Prevention of Acute Exacerbations of COPD. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1908142

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.